bb2121 anti-BCMA CAR T-cell therapy in relapsed/refractory MM
Triple combination therapies for multiple myeloma (MM) patients
Heinz Ludwig et al.
What are the benefits of having different chronic lymphocytic leukemia (CLL) treatment options?
Professional education and training on the management CAR T-cell toxicities
Subcutaneous daratumumab: an update on the latest MM clinical trials
Niels van de Donk